OncoMatch/Clinical Trials/NCT05796570
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Is NCT05796570 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Decitabine and Filgrastim for acute myeloid leukemia.
Treatment: Decitabine · Filgrastim — The purpose of this study is to examine if it is feasible to administer decitabine and filgrastim after allogenic hematopoietic stem cell transplant (HCT) in children and young adults with myelodysplastic syndrome, acute myeloid leukemia and related myeloid disorders, and if the treatment is effective in preventing relapse after HCT. The names of the study drugs involved in this study are: * Decitabine (a nucleoside metabolic inhibitor) * Filgrastim (a recombinant granulocyte colony-stimulating factor (G-CSF)
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Excluded: FLT3 itd mutation
Allowed: NUP28 mutation
Performance status
ECOG/LANSKY/KARNOFSKY 0–2
ECOG performance status ≤2 (Lansky, Karnofsky ≥60%)
Prior therapy
Must have received: allogeneic hematopoietic stem cell transplant
Patients must be receiving an allogeneic hematopoietic stem cell transplant. All donor types and graft sources are permitted. All conditioning regimens are permitted. All GVHD prophylaxis regimens are permitted.
Lab requirements
Blood counts
adequate organ function to be eligible for allogenic HCT as per institutional standard
Kidney function
adequate organ function to be eligible for allogenic HCT as per institutional standard
Liver function
adequate organ function to be eligible for allogenic HCT as per institutional standard
Cardiac function
NYHA class 2B or better for participants with known history or current symptoms of cardiac disease
Participants must have adequate organ function to be eligible for allogenic HCT as per institutional standard. Participants with known history or current symptoms of cardiac disease should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Boston Children's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify